View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
February 27, 2020updated 01 Jun 2021 10:19am

Novavax starts animal testing of coronavirus vaccine candidates

US-based biotechnology company Novavax has begun testing its new coronavirus vaccine candidates in animal models. The company constructed several vaccine candidates against Covid-19.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates


Follow the latest updates of the outbreak on our timeline.

US-based biotechnology company Novavax has begun testing its new coronavirus vaccine candidates in animal models. The company constructed several vaccine candidates against Covid-19.

The company expects that findings from the preclinical testing will help determine an optimal candidate for human studies, with a clinical trial anticipated to begin in May or June.

Novavax’s candidates are based on its recombinant protein nanoparticle technology platform to produce antigens obtained from the coronavirus spike (S) protein.

To boost immune responses, the company plans to leverage its Matrix-M adjuvant with the vaccine candidate.

Novavax president and CEO Stanley Erck said: “Our previous experience working with other coronaviruses, including both MERS and SARS, allowed us to mobilise quickly against COVID-19 and successfully complete the critical preliminary steps to engineer viable vaccine candidates.

“Now that the protein has been expressed stably in our baculovirus system, we aim to identify the optimal candidate and scale up production of sufficient vaccine for preliminary clinical trials.”

Last month, the company announced plans to use its recombinant nanoparticle technology to develop a Covid-19 vaccine candidate.

Novavax previously developed MERS and SARS vaccines, said to have shown encouraging immunogenicity and complete protection in preclinical testing.

Furthermore, the company created a clinically immunogenetic Ebola vaccine candidate, which demonstrated effectiveness in primate studies.


See all Coronavirus vaccines and drugs in the pipeline

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena